JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Avidity Biosciences Inc

Gesloten

SectorGezondheidszorg

49.27 1.55

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

49.27

Max

50.13

Belangrijke statistieken

By Trading Economics

Inkomsten

-42M

-157M

Verkoop

2.3M

3.8M

Winstmarge

-4,089.29

Werknemers

391

EBITDA

-40M

-171M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+39.17% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.7B

7.2B

Vorige openingsprijs

47.72

Vorige sluitingsprijs

49.27

Nieuwssentiment

By Acuity

50%

50%

145 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Avidity Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 aug 2025, 05:47 UTC

Acquisities, Fusies, Overnames

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

22 apr 2025, 09:30 UTC

Top Nieuws

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Peer Vergelijking

Prijswijziging

Avidity Biosciences Inc Prognose

Koersdoel

By TipRanks

39.17% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 68.4 USD  39.17%

Hoogste 96 USD

Laagste 52 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Avidity Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technische score

By Trading Central

25.575 / 32.65Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

145 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat